Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds.

No Responses to “Gene-Sequencing Company Illumina to Sell Cancer Test Developer”

Post a Comment